0001179110-14-010710.txt : 20140626 0001179110-14-010710.hdr.sgml : 20140626 20140619185242 ACCESSION NUMBER: 0001179110-14-010710 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20140617 FILED AS OF DATE: 20140619 DATE AS OF CHANGE: 20140619 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc. CENTRAL INDEX KEY: 0001503802 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 263931704 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 BUSINESS PHONE: 508-975-4820 MAIL ADDRESS: STREET 1: 2 MERCER ROAD CITY: NATICK STATE: MA ZIP: 01760 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kauffman Michael CENTRAL INDEX KEY: 0001364719 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36167 FILM NUMBER: 14931255 MAIL ADDRESS: STREET 1: C/O COMBINATORX, INC. STREET 2: 245 FIRST STREET CITY: CAMBRIDGE STATE: MA ZIP: 02142 4 1 edgar.xml FORM 4 - X0306 4 2014-06-17 0 0001503802 Karyopharm Therapeutics Inc. KPTI 0001364719 Kauffman Michael C/O KARYOPHARM THERAPEUTICS INC. 2 MERCER ROAD NATICK MA 01760 1 1 0 0 Chief Executive Officer Common Stock 2014-06-18 4 S 0 10000 43.1523 D 687596 D Common Stock 2014-06-17 4 S 0 10000 40.3635 D 908963 I By Spouse This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.25 to $43.96, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the spouse of the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $41.00, inclusive. The reporting person undertakes to provide to Karyopharm Therapeutics Inc., any security holder of Karyopharm Therapeutics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) to this Form 4. /s/ Christopher B. Primiano as Attorney-in-Fact for Michael G. Kauffman 2014-06-19